Developmental and Epileptic Encephalopathies  Market
Developmental and Epileptic Encephalopathies (DEE)

Developmental and Epileptic Encephalopathies


Developmental and Epileptic Encephalopathy (DEE) refer to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills.

The syndromes of epileptic encephalopathies with onset in the neonatal period, infancy, and early childhood include early myoclonic encephalopathy, Ohtahara syndrome, West syndrome, Dravet syndrome (severe myoclonic epilepsy in infancy), Lennox–Gastaut syndrome (LGS), Landau–Kleffner syndrome (LKS), Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS), Doose Syndrome (myoclonic atonic epilepsy), CDKL5 deficiency disorder (CDD), Tuberous sclerosis complex (TSC), SCN8A-DEE, and KCNQ2-DEE.


Developmental and Epileptic Encephalopathies Epidemiology Segmentation in the 7MM


  • Prevalent Population of DEE
  • Diagnosed Prevalent Population of DEE



Developmental and Epileptic Encephalopathies Epidemiological Insights Observed in the 7MM (2021)


  • The total diagnosed incident cases of Developmental and Epileptic Encephalopathies observed in the 7MM were observed to be 235K cases in the year 2021
  • The highest diagnosed Developmental and Epileptic Encephalopathies population accounting for 129K cases, was found in the United States in the year 2021, whereas, the lowest population accounted for 23.7K cases found in Japan. 
  • The total diagnosed incident cases of Developmental and Epileptic Encephalopathies observed in EU5 was found to be 81.9K cases. 


Developmental and Epileptic Encephalopathies Market Insight


The market size of Developmental and Epileptic Encephalopathies in the 7MM was found to be approximately USD 1,371 million in 2021, followed by the US (USD 1,030 million), EU5 (USD 288 million), and Japan (USD 53 million) in the year 2021. 

Developmental and Epileptic Encephalopathies Market Strengths

Ztalmy, the first licensed therapy for CDKL5 Deficiency Disorder, was recently approved in the United States, boosting the growth of the DEE market. The vacuum created by a lack of licensed medications will be filled by further R&D advancement.

Developmental and Epileptic Encephalopathies Market Opportunities

The current competitive scenario of DEE is only restricted to a few therapies. Currently, the market seems to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to grab the potential market space of DEE.


Developmental and Epileptic Encephalopathies Emerging Drugs


  • The emerging drugs in the Developmental and Epileptic Encephalopathies market are
  • XEN496
  • Soticlestat
  • Carisbamate
  • EPX-100 (Clemizole HCl)
  • NBI-921352
  • STK-001
  • NBI-827104
  • JBPOS0101
  • PRAX-562
  • EPX-200 (Lorcaserin) 
  • EPX-300
  • LP352 and others

Developmental and Epileptic Encephalopathies Key Players 


The key players working in the Developmental and Epileptic Encephalopathies market are


  • Longboard Pharmaceuticals
  • Epygenix
  • Praxis Precision Medicines
  • BioPharm Solutions
  • Neurocrine Biosciences
  • Stoke Therapeutics
  • SK Life Science
  • Ovid Therapeutics
  • Takeda
  • Xenon Pharmaceuticals and others